Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%
Mesoblast shares fell -4.45% in the first hour of trades on Tuesday as the company announced it has to resubmit an application to the FDA.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
No News & Media currently available.